United States Biotechnology & Medical Research

Inhibrx Inc (INBX)

Track

Ticker: INBX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Inhibrx Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 28 May 2024
Value US$2,972,701.14 | Price 156.15 | Shares 99,739 (-11.5%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-05-30 2024-05-28 S Sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
99,739 -11.5%
156.15
US$2,972,701 		99,739 -11.5% 156.15 US$2,972,701
2024-05-28 2024-05-28 PrS Proposed sale
3.3
THE ECKELMAN LIVING TRUST

Officer

Officer
60,550
311.13
US$1,482,791 		60,550 311.13 US$1,482,791
2024-05-22 2024-05-22 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
38,185
294.43
US$860,179 		38,185 294.43 US$860,179
2024-05-06 2024-05-06 PrS Proposed sale
Deck Kelly

Officer

Officer
19,711
34.24
US$674,905 		19,711 34.24 US$674,905
2024-03-26 2024-03-26 PrS Proposed sale
Deck Kelly

Officer

Officer
2,896
35.40
US$102,518 		2,896 35.40 US$102,518
2024-03-22 2024-03-22 PrS Proposed sale
Deck Kelly

Officer

Officer
110
35.00
US$3,850 		110 35.00 US$3,850
2024-03-21 2024-03-21 PrS Proposed sale
Deck Kelly

Officer

Officer
3,113
35.09
US$109,230 		3,113 35.09 US$109,230
2024-03-20 2024-03-20 PrS Proposed sale
Deck Kelly

Officer

Officer
16,777
35.02
US$587,552 		16,777 35.02 US$587,552
2024-03-13 2024-03-13 PrS Proposed sale
Deck Kelly

Officer

Officer
32,431
35.43
US$1,148,999 		32,431 35.43 US$1,148,999
2024-03-13 2024-03-13 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
1,898
35.33
US$67,062 		1,898 35.33 US$67,062
2024-03-12 2024-03-12 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
24,050
35.25
US$847,856 		24,050 35.25 US$847,856
2024-03-11 2024-03-11 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
13,558
35.32
US$478,827 		13,558 35.32 US$478,827
2024-03-08 2024-03-08 PrS Proposed sale
3.3
Eckelman Brendan P.

Officer

Officer
2,150
35.75
US$76,862 		2,150 35.75 US$76,862
2024-03-08 2024-03-08 PrS Proposed sale
Deck Kelly

Officer

Officer
42,523
35.75
US$1,520,197 		42,523 35.75 US$1,520,197
2024-03-05 2024-03-05 PrS Proposed sale
Deck Kelly

Officer

Officer
10,417
35.72
US$372,095 		10,417 35.72 US$372,095
2024-03-04 2024-03-04 PrS Proposed sale
Deck Kelly

Officer

Officer
62,083
35.43
US$2,199,363 		62,083 35.43 US$2,199,363
2023-08-30 2023-08-28 B Purchase
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
511,627 +inf%
19.35
US$9,899,982 		511,627 +inf% 19.35 US$9,899,982
2023-03-02 2023-03-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
400 -0.0%
24.71
US$9,883 		400 -0.0% 24.71 US$9,883
2023-03-02 2023-03-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
39,600 -1.9%
24.20
US$958,348 		39,600 -1.9% 24.20 US$958,348
2023-03-01 2023-02-28 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
60 -0.0%
25.02
US$1,501 		60 -0.0% 25.02 US$1,501
2023-02-02 2023-02-02 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
1,130 -0.1%
25.89
US$29,261 		1,130 -0.1% 25.89 US$29,261
2023-02-02 2023-02-02 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
10,120 -0.5%
25.40
US$257,094 		10,120 -0.5% 25.40 US$257,094
2023-02-02 2023-02-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
693 -0.0%
25.66
US$17,780 		693 -0.0% 25.66 US$17,780
2023-02-02 2023-02-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
14,608 -0.7%
25.08
US$366,366 		14,608 -0.7% 25.08 US$366,366
2023-02-02 2023-02-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
13,449 -0.6%
24.29
US$326,710 		13,449 -0.6% 24.29 US$326,710
2023-01-24 2023-01-24 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
63 -0.0%
26.11
US$1,645 		63 -0.0% 26.11 US$1,645
2023-01-24 2023-01-24 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
4,272 -0.2%
25.71
US$109,833 		4,272 -0.2% 25.71 US$109,833
2023-01-24 2023-01-23 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
21,665 -0.9%
25.36
US$549,364 		21,665 -0.9% 25.36 US$549,364
2023-01-23 2023-01-23 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
9,500 -0.3%
25.26
US$239,999 		9,500 -0.3% 25.26 US$239,999
2023-01-04 2023-01-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
3,003 -0.1%
23.99
US$72,043 		3,003 -0.1% 23.99 US$72,043
2023-01-04 2023-01-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
4,102 -0.2%
23.11
US$94,786 		4,102 -0.2% 23.11 US$94,786
2023-01-04 2023-01-03 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
2,084 -0.1%
25.09
US$52,293 		2,084 -0.1% 25.09 US$52,293
2023-01-04 2023-01-03 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
8,598 -0.4%
24.36
US$209,426 		8,598 -0.4% 24.36 US$209,426
2023-01-04 2023-01-03 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
22,213 -1.0%
23.41
US$520,051 		22,213 -1.0% 23.41 US$520,051
2022-12-22 2022-12-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
1,959 -0.1%
27.61
US$54,088 		1,959 -0.1% 27.61 US$54,088
2022-12-22 2022-12-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
7,541 -0.2%
26.87
US$202,591 		7,541 -0.2% 26.87 US$202,591
2022-12-20 2022-12-19 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
754 -0.0%
26.29
US$19,820 		754 -0.0% 26.29 US$19,820
2022-12-20 2022-12-19 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
25,246 -1.0%
25.53
US$644,624 		25,246 -1.0% 25.53 US$644,624
2022-12-07 2022-12-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
1,392 -0.1%
28.46
US$39,617 		1,392 -0.1% 28.46 US$39,617
2022-12-07 2022-12-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
17,681 -0.8%
27.57
US$487,493 		17,681 -0.8% 27.57 US$487,493
2022-12-07 2022-12-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
20,927 -1.0%
26.83
US$561,572 		20,927 -1.0% 26.83 US$561,572
2022-11-22 2022-11-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
6,767 -0.2%
30.12
US$203,819 		6,767 -0.2% 30.12 US$203,819
2022-11-22 2022-11-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
2,733 -0.1%
29.33
US$80,153 		2,733 -0.1% 29.33 US$80,153
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
1,150 -0.0%
32.38
US$37,241 		1,150 -0.0% 32.38 US$37,241
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
912 -0.0%
30.67
US$27,969 		912 -0.0% 30.67 US$27,969
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
6,773 -0.3%
30.15
US$204,196 		6,773 -0.3% 30.15 US$204,196
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
1,767 -0.1%
28.86
US$50,991 		1,767 -0.1% 28.86 US$50,991
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
4,333 -0.2%
27.45
US$118,937 		4,333 -0.2% 27.45 US$118,937
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
4,106 -0.2%
26.57
US$109,098 		4,106 -0.2% 26.57 US$109,098
2022-11-18 2022-11-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
6,959 -0.3%
25.36
US$176,477 		6,959 -0.3% 25.36 US$176,477
2022-11-02 2022-11-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
12,349 -0.6%
33.90
US$418,641 		12,349 -0.6% 33.90 US$418,641
2022-11-02 2022-11-01 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
27,651 -1.2%
33.34
US$921,746 		27,651 -1.2% 33.34 US$921,746
2022-10-24 2022-10-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
5,928 -0.2%
30.58
US$181,255 		5,928 -0.2% 30.58 US$181,255
2022-10-24 2022-10-21 PlS Planned sale
1.5
Kayyem Jon Faiz
Non-Executive Director
3,572 -0.1%
29.39
US$104,977 		3,572 -0.1% 29.39 US$104,977
2022-10-18 2022-10-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
121 -0.0%
31.51
US$3,812 		121 -0.0% 31.51 US$3,812
2022-10-18 2022-10-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
2,892 -0.1%
30.81
US$89,090 		2,892 -0.1% 30.81 US$89,090
2022-10-18 2022-10-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
14,006 -0.5%
29.92
US$419,123 		14,006 -0.5% 29.92 US$419,123
2022-10-18 2022-10-17 PlS Planned sale
2.5
Lappe Mark

Chief Executive Officer

Executive Director
8,981 -0.3%
28.66
US$257,419 		8,981 -0.3% 28.66 US$257,419
2022-10-12 2022-10-07 B Purchase
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
333,333 +inf%
30.00
US$9,999,957 		333,333 +inf% 30.00 US$9,999,957
2022-10-12 2022-10-07 B Purchase
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
1,000,000 +70.1%
30.00
US$29,999,900 		1,000,000 +70.1% 30.00 US$29,999,900
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
100 -0.0%
30.52
US$3,052 		100 -0.0% 30.52 US$3,052
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
10,893 -0.5%
29.68
US$323,302 		10,893 -0.5% 29.68 US$323,302
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
5,954 -0.3%
28.97
US$172,495 		5,954 -0.3% 28.97 US$172,495
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
4,262 -0.2%
27.76
US$118,299 		4,262 -0.2% 27.76 US$118,299
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
11,136 -0.5%
26.78
US$298,182 		11,136 -0.5% 26.78 US$298,182
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
6,207 -0.3%
26.06
US$161,763 		6,207 -0.3% 26.06 US$161,763
2022-10-05 2022-10-04 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
1,448 -0.1%
24.67
US$35,720 		1,448 -0.1% 24.67 US$35,720
2022-09-07 2022-09-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
2,493 -0.1%
15.66
US$39,032 		2,493 -0.1% 15.66 US$39,032
2022-09-07 2022-09-06 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
37,507 -1.5%
14.86
US$557,241 		37,507 -1.5% 14.86 US$557,241
2022-08-04 2022-08-03 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
15,500 -0.6%
18.47
US$286,209 		15,500 -0.6% 18.47 US$286,209
2022-08-04 2022-08-02 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
24,500 -1.0%
17.70
US$433,626 		24,500 -1.0% 17.70 US$433,626
2022-07-08 2022-07-07 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
40,000 -1.6%
17.17
US$686,800 		40,000 -1.6% 17.17 US$686,800
2022-04-07 2022-04-05 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Officer
400 -0.0%
25.04
US$10,016 		400 -0.0% 25.04 US$10,016
2021-03-24 2021-03-24 PlS Planned sale
3.3
Eckelman Brendan P.

Chief Scientific Officer

Executive Director
17,000 -0.7%
19.02
US$323,340 		17,000 -0.7% 19.02 US$323,340
2021-02-18 2021-02-17 PlS Planned sale
Wagner Klaus W.

Chief Medical Officer

Officer
19,559 -8.3%
25.29
US$494,647 		19,559 -8.3% 25.29 US$494,647
Explore more

More insider trading research around Inhibrx Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America